It's best to have patients on aggressive lipid-lowering therapy before discharge after an acute ST-segment elevation myocardial infarction (STEMI), so why not start it right away — even in the cath lab — using some of the most potentLDL-lowering agents available?

That was a main idea behind the randomized, sham-controlled EPIC-STEMI trial, in which...